Literature DB >> 16454537

The Erice declaration : the critical role of communication in drug safety.

Bruce Hugman1.   

Abstract

The Erice Declaration on Communicating Drug Safety Information, first published in September 1997, provides a vision of vigorous, open, ethical, patient-centred communications in drug safety that the world has yet to achieve. The Declaration is reprinted here as a further stimulus to all parties to renew their commitment and to add new momentum to the improvements which have undoubtedly taken place in the past few years. The content of the Declaration is briefly reviewed, and some of the continuing communications challenges and problems are outlined.

Entities:  

Mesh:

Year:  2006        PMID: 16454537     DOI: 10.2165/00002018-200629010-00007

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  7 in total

Review 1.  The combined oral contraceptive pill--are poor communication systems responsible for loss of confidence in this contraceptive method?

Authors:  A Mills; I R Edwards
Journal:  Hum Reprod       Date:  1999-01       Impact factor: 6.918

2.  Developing an optimal approach to global drug safety.

Authors:  R Balkrishnan; C D Furberg
Journal:  J Intern Med       Date:  2001-10       Impact factor: 8.989

3.  Communicating drug-safety information.

Authors:  D McNamee
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

4.  Liver enzyme monitoring in patients treated with troglitazone.

Authors:  D J Graham; C R Drinkard; D Shatin; Y Tsong; M J Burgess
Journal:  JAMA       Date:  2001-08-15       Impact factor: 56.272

5.  The WHO World Alliance for Patient Safety: a new challenge or an old one neglected?

Authors:  I Ralph Edwards
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

6.  Contraindicated use of cisapride: impact of food and drug administration regulatory action.

Authors:  W Smalley; D Shatin; D K Wysowski; J Gurwitz; S E Andrade; M Goodman; K A Chan; R Platt; S D Schech; W A Ray
Journal:  JAMA       Date:  2000-12-20       Impact factor: 56.272

7.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.

Authors:  Munir Pirmohamed; Sally James; Shaun Meakin; Chris Green; Andrew K Scott; Thomas J Walley; Keith Farrar; B Kevin Park; Alasdair M Breckenridge
Journal:  BMJ       Date:  2004-07-03
  7 in total
  13 in total

Review 1.  Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.

Authors:  Craig G Hartford; Kasia S Petchel; Hani Mickail; Susana Perez-Gutthann; Mary McHale; John M Grana; Paula Marquez
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  An industry perspective on the Erice declaration and risk minimisation plans.

Authors:  Simon Ingate; Deborah Tranter; Anjan Banerjee; Andrew Hobbs
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Intelligent risk communication: can it be improved?

Authors:  Andrzej Czarnecki
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

4.  Poisons centres and the reporting of adverse drug events: the case for further development.

Authors:  Glyn N Volans; Lakshman Karalliedde; Heather M Wiseman
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

5.  The good old drugs!

Authors:  I Ralph Edwards
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 6.  Pharmaceutical Benefit-Risk Communication Tools: A Review of the Literature.

Authors:  Dominic Way; Hortense Blazsin; Ragnar Löfstedt; Frederic Bouder
Journal:  Drug Saf       Date:  2017-01       Impact factor: 5.606

7.  Adverse drug reaction reporting by patients: an overview of fifty countries.

Authors:  Florence Margraff; Delphine Bertram
Journal:  Drug Saf       Date:  2014-06       Impact factor: 5.606

Review 8.  Pharmacovigilance: methods, recent developments and future perspectives.

Authors:  L Härmark; A C van Grootheest
Journal:  Eur J Clin Pharmacol       Date:  2008-06-04       Impact factor: 2.953

9.  Pattern and quality of scientific communications on drug safety produced by a regional pharmacovigilance center in Nepal.

Authors:  Subish Palaian; Mohamed I M Ibrahim; Pranaya Mishra
Journal:  Pharm Pract (Granada)       Date:  2010-03-15

10.  Pharmacovigilance in Calabria (Italy): Local experiences resonate international relevance.

Authors:  Emilio Russo; Giovambattista De Sarro
Journal:  J Pharmacol Pharmacother       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.